medigraphic.com
Colegio de Medicina Interna de México.

2023, Number 2

<< Back Next >>

Med Int Mex 2023; 39 (2)

Multidisciplinary approach of overweight and obesity in adults

Meneses-Sierra E, Ochoa-Martínez C, Burciaga-Jiménez E, Gómez-Mendoza R, Salgado-Loza JL, Peña-Arriaga TM, Díaz-Aguilera M, Burguete-García AI, Márquez-González SM, Zavala-Cruz GG, Tenorio-Aguirre EK, Farfán-Salazar G, Nava-González EJ, Zerrweck C, Ramírez-Velásquez JE, Ponce-López ML, Sierra-Salazar M, Gutiérrez-Aguirre CH, Maldonado-Pintado DG, Sánchez-Mijangos JH, Luna-Fuentes R, Sandoval-Gutiérrez JL, Barriguete-Meléndez JA, Anda-Garay JC, Barrera-Cruz RJ, Morales-Gómez F, Vargas-Pedraza ME, Meneses-Vargas DE, Ayala-Calvillo E, Silva-Olvera MR, Pérez-Fernández BE, Ramírez-Huerta AC, Aguilar-Barrera ES, Hernández-Arizpe LM, Reséndiz-Barragán AM, García-Quiroz CA, Cortés-Vargas F, Chaidez-Ojeda BN, Canché-Arenas AP, Reyes-García JG, Reyes-Castillo E

Language: Spanish
References: 133
Page: 329-366
PDF size: 369.32 Kb.


ABSTRACT

Obesity and overweight are defined as: “the abnormal or excessive accumulation of fat that can be detrimental to health”. The increase in the percentage of body fat is directly associated with the appearance of multiple comorbidities and serious consequences, since it predisposes or favors the development of cardiovascular risk factors, such as arterial hypertension, dyslipidemia, glucose intolerance, diabetes, heart disease and other related diseases. This document aims to synthesize information concerning overweight and obesity in adults so that general practitioners, specialists and subspecialists within their clinical practice can provide adequate diagnosis, treatment, primary and secondary prevention based on the best information and scientific evidence for decision making and reduce the economic and epidemiological burden caused by this disease to the Mexican population.


REFERENCES

  1. Obesidad [Internet]. [cited 2022 Oct 9]. Available from:https://www.who.int/es/health-topics/obesity#tab=tab_1.

  2. Obesity: preventing and managing the global epidemic :report of a WHO consultation [Internet]. [cited 2022Oct 9]. Available from: https://apps.who.int/iris/handle/10665/42330.

  3. Petrova D, Salamanca-Fernández E, Rodríguez BarrancoM, Navarro Pérez P, Jiménez-Moleón JJ, Sánchez MJ. Laobesidad como factor de riesgo en personas con COVID-19:posibles mecanismos e implicaciones. Atención Primaria2020; 52 (7): 496-500.

  4. Withrow D, Alter DA. The economic burden of obesityworldwide: a systematic review of the direct costs of obesity.Obes Rev 2011; 12 (2): 131-41. doi: 10.1111/j.1467-789X.2009.00712.x.

  5. Kolotkin RL, Meter K, Williams GR. Quality of life andobesity. Obes Rev 2001; 2 (4): 219-29. doi: 10.1046/j.1467-789x.2001.00040.x.

  6. Durrer Schutz D, Busetto L, Dicker D, Farpour-Lambert N,Pryke R, Toplak H, et al. European Practical and Patient-Centred Guidelines for Adult Obesity Managementin Primary Care. Obes Facts 2019; 12 (1): 40-66. doi:10.1159/000496183.

  7. Yumuk V, Tsigos C, Fried M, Schindler K, Busetto L,Micic D, et al. European Guidelines for Obesity Managementin Adults. Obes Facts 2015; 8 (6): 402-24. doi:10.1159/000442721.

  8. Semlitsch T, Stigler FL, Jeitler K, Horvath K, Siebenhofer A.Management of overweight and obesity in primary care-A systematic overview of international evidence-basedguidelines. Obes Rev 2019; 20 (9): 1218-30. doi: 10.1111/obr.12889.

  9. Rivera-Dommarco J, Colchero M, Fuentes M, González deCosío Martínez T, Aguilar Salinas C, Hernández Licona G,et al. La obesidad en México: Estado de la política públicay recomendaciones para su prevención y control. INSP2018: 190-200.

  10. Di Cesare M, Bentham J, Stevens GA, Zhou B, Danaei G, Lu Y,et al. Trends in adult body-mass index in 200 countries from1975 to 2014: A pooled analysis of 1698 population-basedmeasurement studies with 19.2 million participants. Lancet2016; 387 (10026): 1377-96. http://dx.doi.org/10.1016/S0140-6736(16)30054-X.

  11. Obesidad y sobrepeso [Internet]. [cited 2022 Oct 17].Available from: https://www.who.int/es/news-room/factsheets/detail/obesity-and-overweight.

  12. Lobstein T, Brinsden H, Neveux M. World Obesity Atlas2022 [Internet]. World Obesity Federation; 2022. Availablefrom: https://policycommons.net/artifacts/2266990/world_obesity_atlas_2022_web/.

  13. Rojas-Martínez R, Basto-Abreu A, Aguilar-Salinas CA,Zárate-Rojas E, Villalpando S, Barrientos-Gutiérrez T. Prevalenceof previously diagnosed diabetes mellitus in Mexico.Salud Publica Mex 2018; 60 (3): 224-32.

  14. Hall JE, Do Carmo JM, Da Silva AA, Wang Z, Hall ME. Obesity-induced hypertension: Interaction of neurohumoraland renal mechanisms. Circ Res 2015; 116 (6): 991-1006.doi: 10.1161/CIRCRESAHA.116.305697.

  15. Hay SI, Abajobir AA, Abate KH, Abbafati C, Abbas KM,Abd-Allah F, et al. Global, regional, and national disabilityadjustedlife-years (DALYs) for 333 diseases and injuriesand healthy life expectancy (HALE) for 195 countries andterritories, 1990-2016: A systematic analysis for the GlobalBurden of Disease Study 2016. Lancet 2017; 390 (10100):1260-344. doi: 10.1016/S0140-6736(17)32130-X.

  16. Barquera S, Campos I, Rivera JA. Mexico attempts to tackleobesity: The process, results, push backs and futurechallenges. Obes Rev 2013; 14 (S2): 69-78. doi: 10.1111/obr.12096.

  17. Shamah-Levy T, Romero-Martínez M, Barrientos-GutiérrezT, Cuevas-Nasu L, Bautista-Arredondo S, Colchero MA,Gaona-Pineda EB, Lazcano-Ponce E, Martínez-BarnetcheJ, Alpuche-Arana CR-DJ. Continua Encuesta Nacionalde Salud y Nutricion 2021 sobre Covid-19 [Internet].2021. 324 p. Available from: https://www.insp.mx/resources/images/stories/2022/docs/220801_Ensa21_digital_29julio.pdf.

  18. Shamah LT, Cuevas NL, Romero MM, Gaona PEB, GómezALM, Mendoza AL, et al. Encuesta Nacional de Salud yNutrición 2018-19. Resultados Nacionales [Internet].Instituto Nacional de Salud Pública. 2020; 268 p. Availablefrom: https://ensanut.insp.mx/encuestas/ensanut2018/informes.php.

  19. Tsao CW, Aday AW, Almarzooq ZI, Alonso A, Beaton AZ, BittencourtMS, et al. Heart disease and stroke statistics-2022update: A report from the American Heart Association.Circulation 2022; 145: 153-639. https://doi.org/10.1161/CIR.0000000000001052.

  20. Bray GA, Kim KK, Wilding JPH, World Obesity Federation.Obesity: a chronic relapsing progressive disease process.A position statement of the World Obesity Federation.Obes Rev 2017; 18 (7): 715-723. doi: 10.1111/obr.12551.

  21. Keys A, Fidanza F, Karvonen MJ, Kimura N, Taylor HL. Indicesof relative weight and obesity. Int J Epidemiol 1972; 25 (6):329-43. doi: 10.1093/ije/dyu058.

  22. Beaufrère B, Morio B. Fat and protein redistribution withaging: metabolic considerations. Eur J Clin Nutr 2000; 54Suppl 3: S48-53. doi: 10.1038/sj.ejcn.1601025.

  23. Taylor RW, Keil D, Gold EJ, Williams SM, Goulding A. Bodymass index, waist girth, and waist-to-hip ratio as indexesof total and regional adiposity in women: evaluation usingreceiver operating characteristic curves. Am J Clin Nutr1998; 67 (1): 44-9. doi: 10.1093/ajcn/67.1.44.

  24. Suárez-Carmona W, Sánchez-Oliver AJ. Índice de masacorporal: ventajas y desventajas de su uso en la obesidad.Relación con la fuerza y la actividad física. Nutr Clin Med2018; XII (3): 128-39. DOI: 10.7400/NCM.2018.12.3.5067.

  25. Garvey WT, Mechanick JI, Brett EM, Garber AJ, HurleyDL, Jastreboff AM, et al. American Association of ClinicalEndocrinologists and American College of EndocrinologyComprehensive Clinical Practice Guidelines for MedicalCare of Patients with Obesity. Endocr Pract 2016; 22 Suppl3: 1-203. doi: 10.4158/EP161365.GL.

  26. Nimptsch K, Konigorski S, Pischon T. Diagnosis of obesityand use of obesity biomarkers in science and clinical medicine.Metabolism 2019; 92 (2019): 61-70. https://doi.org/10.1016/j.metabol.2018.12.006.

  27. Kuk JL, Ardern CI, Church TS, Sharma AM, Padwal R, Sui X,et al. Edmonton Obesity Staging System: association withweight history and mortality risk. Appl Physiol Nutr Metab2011; 36 (4): 570-6. doi: 10.1139/h11-058.

  28. Sharma AM, Kushner RF. A proposed clinical staging systemfor obesity. Int J Obes 2009; 33 (3): 289-95. doi: 10.1038/ijo.2009.2.

  29. Rueda-Clausen CF, Poddar M, Lear S, Poirier P, et al. Assessmentof people living with obesity. Canadian AdultObesity Clinical Practice Guidelines 2020; 1-17.

  30. Malik VS, Willett WC, Hu FB. Global obesity: Trends, riskfactors and policy implications. Nat Rev Endocrinol 2013;9 (1): 13-27. http://dx.doi.org/10.1038/nrendo.2012.199.

  31. Domínguez-Vásquez P, Olivares S, Santos JL. Influenciafamiliar sobre la conducta alimentaria y su relación con laobesidad infantil. Arch Latinoam Nutr 2008; 58 (3): 249-55.

  32. Behar R, Arancibia M. Trastornos alimentarios maternos ysu influencia en la conducta alimentaria de sus hijas(os).Rev Chil Pediatr 2014; 85 (6): 731-9.

  33. Esquivias-Zavala H, Reséndiz-Barragán AM, García F, Elías-López D. La salud mental en el paciente con obesidad en protocolopara cirugía bariátrica. Salud Ment 2016; 39 (3): 165-73.

  34. Bray GA, Heisel WE, Afshin A, Jensen MD, Dietz WH, LongM, et al. The science of obesity management: An EndocrineSociety Scientific Statement. Endocr Rev 2018; 39 (2): 79-132. https://doi.org/10.1210/er.2017-00253.

  35. Piché ME, Tchernof A, Després JP. Obesity phenotypes,diabetes, and cardiovascular diseases. Circ Res 2020;1477-500.

  36. Dambha-Miller H, Day AJ, Strelitz J, Irving G, Griffin SJ.Behaviour change, weight loss and remission of Type 2diabetes: a community-based prospective cohort study.Diabet Med 2020; 37 (4): 681-8. doi: 10.1111/dme.14122.

  37. Powell-Wiley TM, Poirier P, Burke LE, Després JP, Gordon-Larsen P, Lavie CJ, et al. Obesity and cardiovascular disease:A scientific statement from the American Heart Association.Circulation 2021; 143 (21): E984-1010. doi: 10.1161/CIR.0000000000000973.

  38. Cariou B. The metabolic triad of non-alcoholic fatty liverdisease, visceral adiposity and type 2 diabetes: Implicationsfor treatment. Diabetes Obes Metab 2022; 24 (S2): 15-27.https://doi.org/10.1111/dom.14651.

  39. Jehan S, Zizi F, Pandi-Perumal SR, Wall S, Auguste E, MyersAK, et al. Obstructive sleep apnea and obesity: Implicationsfor public health. Sleep Med Disord Int J 2017; 1 (4).

  40. Baltieri L, Cazzo E, de Souza AL, Alegre SM, de Paula VieiraR, Antunes E, et al. Influence of weight loss on pulmonaryfunction and levels of adipokines among asthmatic individualswith obesity: One-year follow-up. Respir Med 2018;145: 48-56. https://doi.org/10.1016/j.rmed.2018.10.017.

  41. Nazar J. C, Coloma D. R, Contreras C. JI, Molina P. I, FuentesH. R. Consideraciones perioperatorias en el paciente obeso.Rev Chil Cirugía 2018; 70 (6): 580-8.

  42. Lundstrøm LH, Møller AM, Rosenstock C, Astrup G, WetterslevJ. High body mass index is a weak predictor fordifficult and failed tracheal intubation: a cohort study of91,332 consecutive patients scheduled for direct laryngoscopyregistered in the Danish Anesthesia Database.Anesthesiology 2009; 110 (2): 266-74.

  43. Obesity and Cancer Fact Sheet - NCI [Internet]. Availablefrom: https://www.cancer.gov/about-cancer/causesprevention/risk/obesity/obesity-fact-sheet.

  44. Fruh SM. Obesity: Risk factors, complications, and strategiesfor sustainable long‐term weight management.J Am Assoc Nurse Pract 2017; 29 (S1): S3-S14. doi:10.1002/2327-6924.12510.

  45. Mariona FG. Perspectives in obesity and pregnancy.Womens Health (Lond) 2016; 12 (6): 523-32. doi:10.1177/1745505716686101.

  46. Rehder PM, Borovac-Pinheiro A, de Araujo ROMB, DinizJAPM, Ferreira NLC, Branco ACR, et al. Gestational diabetesmellitus and obesity are related to persistent hyperglycemiain the postpartum period. Rev Bras Ginecol Obstet2021; 43 (2): 107-12. doi: 10.1055/s-0040-1721356.

  47. Committee ADAPP. 2. Classification and diagnosis ofdiabetes: Standards of medical care in diabetes—2022.Diabetes Care 2021; 45 (Supplement_1): S17-38. https://doi.org/10.2337/dc22-S002.

  48. Flores L, Solorio I, Melo M, Trejo J. Embarazo y obesidad:Riesgo para desarrollo de diabetes gestacional en lafrontera norte de México. Gac Med Mex 2014; 150: 73-8.

  49. Spradley FT. Metabolic abnormalities and obesity’s impacton the risk for developing preeclampsia. Am J Physiol RegulIntegr Comp Physiol 2017; 312 (1): R5-12.

  50. Olerich K, Soper D, Delaney S, Sterrett M. Pregnancy carefor patients with super morbid obesity. Front Pediatr 2022;10: 839377. doi: 10.3389/fped.2022.839377.

  51. Harge D, Spiegler J, Schoeer A, Deckwart V, eichert J. Maternalsuper-obesity. Arch Gynecol Obstet 2016; 293 (5):987-992. doi: 10.1007/s00404-015-3921-9.

  52. Davidson KW, Barry MJ, Mangione CM, Cabana M, CaugheyAB, Davis EM, et al. Behavioral counseling interventions forhealthy weight and weight gain in pregnancy: US PreventiveServices Task Force Recommendation Statement. JAMA2021; 325 (20): 2087-93. doi: 10.1001/jama.2021.6949.

  53. Raynor HA, Champagne CM. Position of the Academy ofNutrition and Dietetics: Interventions for the treatmentof overweight and obesity in adults. J Acad Nutr Diet2016; 116 (1): 129-47. https://doi.org/10.1016/j.jand.2015.10.031.

  54. Gonzalez-Campoy JM, St Jeor ST, Castorino K, Ebrahim A, HurleyD, Jovanovic L, et al. Clinical practice guidelines for healthyeating for the prevention and treatment of metabolic andendocrine diseases in adults: cosponsored by the AmericanAssociation of Clinical Endocrinologists/the American Collegeof Endocrinology and the Obesity Society. Endocr Pract 2013;19 Suppl 3: 1-82. doi: 10.4158/EP13155.GL.

  55. Großkopf A, Simm A. Carbohydrates in nutrition: friend orfoe? Z Gerontol Geriatr 2020; 53 (4): 290-4. doi: 10.1007/s00391-020-01726-1.

  56. Gong X, An Q, Le L, Geng F, Jiang L, Yan J, et al. Prospectsof cereal protein-derived bioactive peptides: Sources,bioactivities diversity, and production. Crit Rev Food SciNutr 2022; 62 (11): 2855-71. https://doi.org/10.1080/10408398.2020.1860897.

  57. Ge L, Sadeghirad B, Ball GDC, da Costa BR, Hitchcock CL,Svendrovski A, et al. Comparison of dietary macronutrientpatterns of 14 popular named dietary programmes forweight and cardiovascular risk factor reduction in adults:systematic review and network meta-analysis of randomisedtrials. BMJ 2020; 369: m696. doi: 10.1136/bmj.m696.

  58. Muscogiuri G, El Ghoch M, Colao A, Hassapidou M, YumukV, Busetto L. European Guidelines for Obesity Managementin Adults with a Very Low-Calorie Ketogenic Diet: Asystematic review and meta-analysis. Obes Facts 2021; 14:222-45. doi: 10.1159/000515381.

  59. Diabetes Prevention Program (DPP) Research Group. TheDiabetes Prevention Program (DPP): description of lifestyleintervention. Diabetes Care 2002; 25 (12): 2165-71. doi:10.2337/diacare.25.12.2165.

  60. Gong Q, Zhang P, Wang J, Ma J, An Y, Chen Y, et al. Morbidityand mortality after lifestyle intervention for peoplewith impaired glucose tolerance: 30-year results of the DaQing Diabetes Prevention Outcome Study. Lancet DiabetesEndocrinol 2019; 7 (6): 452-61. https://doi.org/10.1016/S2213-8587(19)30093-2.

  61. Vitolins MZ, Anderson AM, Delahanty L, Raynor H, MillerGD, Mobley C, et al. Action for health in diabetes (LookAHEAD) trial: Baseline evaluation of selected nutrients andfood group intake. J Am Diet Assoc 2009; 109 (8): 1367-75.doi: 10.1016/j.jada.2009.05.016.

  62. Heymsfield SB, Wadden TA. Mechanisms, pathophysiology,and management of obesity. N Engl J Med 2017; 376 (3):254-66. doi: 10.1056/NEJMra1514009.

  63. Thomas DM, Martin CK, Lettieri S, Bredlau C, Kaiser K,Church T, et al. Can a weight loss of one pound a weekbe achieved with a 3500-kcal deficit? Commentary on acommonly accepted rule. Int J Obes 2013; 37 (12): 1611-3.doi: 10.1038/ijo.2013.51.

  64. Jensen MD, Ryan DH, Apovian CM, Ard JD, Comuzzie AG,Donato KA, et al. 2013 AHA/ACC/TOS guideline for themanagement of overweight and obesity in adults: a reportof the American College of Cardiology/American Heart AssociationTask Force on Practice Guidelines and The ObesitySociety. Circulation 2014; 129 (25 Suppl 2): S102-38. doi:10.1161/01.cir.0000437739.71477.ee.

  65. Ewy MW, Patel A, Abdelmagid MG, Mohamed Elfadil O,Bonnes SL, Salonen BR, et al. Plant-based diet: Is it asgood as an animal-based diet when it comes to protein?Curr Nutr Rep. 2022; 11 (2): 337-46. doi: 10.1007/s13668-022-00401-8.

  66. Harrison S, Lemieux S, Lamarche B. Assessing the impactof replacing foods high in saturated fats with foods high inunsaturated fats on dietary fat intake among Canadians.Am J Clin Nutr 2022; 115 (3): 877-85. doi: 10.1093/ajcn/nqab420.

  67. Sacks FM, Bray GA, Carey VJ, Smith SR, Ryan DH, AntonSD, et al. Comparison of weight-loss diets with differentcompositions of fat, protein, and carbohydrates.N Engl J Med 2009; 360 (9): 859-73. doi: 10.1056/NEJMoa0804748.

  68. Clifton PM, Condo D, Keogh JB. Long term weight maintenanceafter advice to consume low carbohydrate, higherprotein diets--a systematic review and meta analysis. NutrMetab Cardiovasc Dis 2014; 24 (3): 224-35. doi: 10.1016/j.numecd.2013.11.006.

  69. Chiavaroli L, Viguiliouk E, Nishi SK, Blanco Mejia S, RahelićD, Kahleová H, et al. DASH dietary pattern and cardiometabolicoutcomes: An umbrella review of systematic reviewsand meta-analyses. Nutrients. 2019; 11 (2). 11(2): 338. doi:10.3390/nu11020338.

  70. Endocrinology TEOTLD. Retraction and republication-Effectof a high-fat Mediterranean diet on bodyweight andwaist circumference: a prespecified secondary outcomesanalysis of the PREDIMED randomised controlled trial.Lancet Diabet Endocrinol 2019; 7 (5): 334. doi: 10.1016/S2213-8587(19)30074-9.

  71. Wharton S, Lau DCW, Vallis M, Sharma AM, Biertho L,Campbell-Scherer D, et al. Obesity in adults: A clinicalpractice guideline. CMAJ 2020; 192 (31): E875-91. doi:10.1503/cmaj.191707.

  72. Wilson K. Obesity: Lifestyle modification and behaviorinterventions. FP Essent. 2020; 492: 19-24.

  73. Ferguson B. ACSM’s Guidelines for Exercise Testing andPrescription 9th ed. 2014. J Can Chiropr Assoc 2014;58: 328.

  74. American College of Sports Medicine. Manual ACSM parala valoración y prescripción del ejercicio. 3rd ed. 2014:252-256.

  75. Quintero Y, Bastardo G, Angarita C, Rivas Cordova JG, SuarezCI, Uzcategui A. El estudio de la obesidad desde diversasdisciplinas. Múltiples enfoques una misma visión. RevVenez Endocrinol y Metab 2020; 18 (3): 95-106.

  76. Vista de las estrategias de la terapia cognitivo conductual(TCC) para pacientes de cirugía bariátrica: revisión sistemática.2022.

  77. Haltiwanger EP. Effect of a group adherence interventionfor Mexican-American older adults with type 2 diabetes.Am J Occup Ther 2012; 66 (4): 447-54. https://doi.org/10.5014/ajot.2012.004457.

  78. Asinsten JC. Aulas expandidas: la potenciación de la educaciónpresencial. Rev Univ La Salle 2013; 60 (1): 97-113.

  79. Warren JM, Smith N, Ashwell M. A structured literaturereview on the role of mindfulness, mindful eating and intuitiveeating in changing eating behaviours: effectivenessand associated potential mechanisms. Nutr Res Rev 2017;30 (2): 272-83. doi: 10.1017/S0954422417000154.

  80. Fuentes Artiles R, Staub K, Aldakak L, Eppenberger P, RühliF, Bender N. Mindful eating and common diet programslower body weight similarly: Systematic review and metaanalysis.Obes Rev 2019; 20 (11): 1619-27. doi: 10.1111/obr.12918.

  81. Forman EM, Manasse SM, Butryn ML, Crosby RD, Dallal DH,Crochiere RJ. Long-term follow-up of the mind your healthproject: Acceptance-based versus standard behavioraltreatment for obesity. Obesity 2019; 27 (4): 565-71. doi:10.1002/oby.22412.

  82. Caixas A. Tratamiento farmacológico de la obesidad. Endocrinoly Nutr 2000; 47 (1): 16.

  83. Dent R, McPherson R, Harper M-E. Factors affecting weightloss variability in obesity. Metabolism 2020; 113: 154388.doi: 10.1016/j.metabol.2020.154388.

  84. Gadde KM, Apolzan JW, Berthoud H-R. Pharmacotherapyfor patients with obesity. Clin Chem 2018; 64 (1): 118-29.doi: 10.1373/clinchem.2017.272815.

  85. Maccora C, Ciuoli C, Goracci A, Benenati N, Formichi C,Pilli T, et al. One month weight loss predicts the efficacyof liraglutide in obese patients: data from a single center.Endocr Pract 2020; 26 (2): 235-40. https://doi.org/10.4158/EP-2019-0169.

  86. Rocha-González HI, De la Cruz-Álvarez LE, Kammar-GarcíaA, Canizales-Quinteros S, Huerta-Cruz JC, Barranco-GarduñoLM, et al. Weight loss at first month and developmentof tolerance as possible predictors of 30 mg phentermineefficacy at 6 months. J Pers Med 2021; 11 (12): 354. doi:10.3390/jpm11121354.

  87. Huerta-Cruz JC, Rocha-González HI, Kammar-García A, Canizales-Quinteros S, Barranco-Garduño LM, Reyes-García JG.Combined first month body weight loss and developmentof tolerance as predictors of 6-month efficacy of mazindolin mild and moderate obese subjects. J Clin Med 2022; 11(11): 3211. doi: 10.3390/jcm11113211.

  88. Müller TD, Finan B, Bloom SR, D’Alessio D, Drucker DJ, FlattPR, et al. Glucagon-like peptide 1 (GLP-1). Mol Metab 2019;30: 72-130. doi: 10.1016/j.molmet.2019.09.010.

  89. Davies MJ, Bergenstal R, Bode B, Kushner RF, Lewin A,Skjøth TV, et al. Efficacy of liraglutide for weight lossamong patients with type 2 diabetes: The SCALE DiabetesRandomized Clinical Trial. JAMA 2015; 314 (7): 687-99. doi:10.1001/jama.2015.9676.

  90. Wilding JPH, Batterham RL, Calanna S, Davies M, Van GaalLF, Lingvay I, et al. Once-weekly semaglutide in adults withoverweight or obesity. N Engl J Med 2021; 384 (11): 989-1002. DOI: 10.1056/NEJMoa2032183.

  91. Ahrén B, Masmiquel L, Kumar H, Sargin M, Karsbøl JD,Jacobsen SH, et al. Efficacy and safety of once-weekly semaglutideversus once-daily sitagliptin as an add-on to metformin,thiazolidinediones, or both, in patients with type 2diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a,randomised trial. lancet Diabetes Endocrinol 2017; 5 (5):341-54. https://doi.org/10.1016/S2213-8587(17)30092-X.

  92. Aroda VR, Bain SC, Cariou B, Piletič M, Rose L, Axelsen M,et al. Efficacy and safety of once-weekly semaglutide versusonce-daily insulin glargine as add-on to metformin (with orwithout sulfonylureas) in insulin-naive patients with type 2diabetes (SUSTAIN 4): a randomised, open-label, parallelgroup,multicentre, multinational, phase 3a trial. LancetDiabetes Endocrinol 2017; 5 (5): 355-66. doi: 10.1016/S2213-8587(17)30085-2.

  93. Wadden TA, Bailey TS, Billings LK, Davies M, Frias JP,Koroleva A, et al. Effect of subcutaneous semaglutide vsplacebo as an adjunct to intensive behavioral therapy onbody weight in adults with overweight or obesity: The STEP3 randomized clinical trial. JAMA 2021; 325 (14): 1403-13.doi: 10.1001/jama.2021.1831.

  94. Mann JFE, Nauck MA, Nissen SE, Pocock S, Ph D, ZinmanB, et al. Liraglutide and cardiovascular outcomes in type 2diabetes. Drug Ther Bull 2016; 54 (9): 101.

  95. Gadde KM, Heymsfield SB. Targeting visceral adiposity withpharmacotherapy. Lancet Diabetes Endocrinol 2021; 9 (9):551-2. doi: 10.1016/S2213-8587(21)00204-7.

  96. Gadde KM, Allison DB, Ryan DH, Peterson CA, Troupin B,Schwiers ML, et al. Effects of low-dose, controlled-release,phentermine plus topiramate combination on weight andassociated comorbidities in overweight and obese adults(CONQUER): a randomised, placebo-controlled, phase3 trial. Lancet (London) 2011; 377 (9774): 1341-52. doi:10.1016/S0140-6736(11)60205-5.

  97. Hollander P, Gupta AK, Plodkowski R, Greenway F, BaysH, Burns C, et al. Effects of naltrexone sustained- release/bupropion sustained-release combination therapy on bodyweight and glycemic parameters in overweight and obesepatients with type 2 diabetes. Diabetes Care 2013; 36 (12):4022-9. https://doi.org/10.2337/dc13-0234.

  98. Apovian CM, Istfan NW. Obesity: guidelines, best practices,new research. Endocrinol Metab Clin North Am 2016; 45:xvii-xviii. doi: 10.1016/j.ecl.2016.06.014.

  99. Aronne LJ, Wadden TA, Peterson C, Winslow D, Odeh S,Gadde KM. Evaluation of phentermine and topiramateversus phentermine/topiramate extended-release in obeseadults. Obesity (Silver Spring) 2013; 21 (11): 2163-71. doi:10.1002/oby.20584.

  100. Powell A. Obesity: Pharmacotherapy. FP Essent 2020;492: 25-9.

  101. D’A Mesnier CRTT. No Title. In: Uso de clobenzorex en fasesdiscontinuas en pacientes con sobrepeso. 1989.

  102. Mirouze J. Etude en double insu avec permutation croiseed’une substance anorexigene: le clobenzorex. 1973.

  103. Torgerson JS, Hauptman J, Boldrin MN, Sjöström L. XENicalin the prevention of diabetes in obese subjects (XENDOS)study: a randomized study of orlistat as an adjunct tolifestyle changes for the prevention of type 2 diabetes inobese patients. Diabetes Care 2004; 27 (1): 155-61. doi:10.2337/diacare.27.1.155.

  104. Lucchetta RC, Riveros BS, Pontarolo R, Radominski RB,Otuki MF, Fernandez-Llimos F, et al. Systematic review andmeta-analysis of the efficacy and safety of amfepramoneand mazindol as a monotherapy for the treatment of obeseor overweight patients. Clinics (Sao Paulo) 2017; 72 (5):317-24. doi: 10.6061/clinics/2017(05)10.

  105. Soto-Molina H, Pizarro-Castellanos M, Rosado-Pérez J,Rizzoli-Córdoba A, Lara-Padilla E, del Valle-Laisequilla CF,et al. Six-month efficacy and safety of amfepramone inobese Mexican patients: a double-blinded, randomized,controlled trial. Int J Clin Pharmacol Ther 2015; 53 (7):541-9. doi: 10.5414/CP202135.

  106. De Oliveira MH, Ferreira PCL, Carlos G, Salazar FR, BergoldAM, Pechansky F, et al. Pharmacokinetics study ofmazindol in plasma, oral fluid, and urine of volunteers.Eur J Clin Pharmacol 2016; 72 (8): 945-51. doi: 10.1007/s00228-016-2055-8.

  107. Miranda-Garduño LM, Reza-Albarrán A. Obesidad, inflamacióny diabetes. Gac Méd Méx 2008; 144 (1): 39-46.

  108. Romero P, Priego A, Valdecabres C, Real JT, Ascaso JF,Carmena R. Cuantificación de insulinorresistencia con losvalores de insulina basal e índice HOMA en una poblaciónno diabética. Med Clínica 2001; 117: 530-3.

  109. Hoffman R, Al’Absi M. Khat use and neurobehavioralfunctions: suggestions for future studies. J Ethnopharmacol2010; 132 (3): 554-63. doi: 10.1016/j.jep.2010.05.033.

  110. Kalyanasundar B, Perez CI, Arroyo B, Moreno MG, GutierrezR. The appetite suppressant D-norpseudoephedrine(Cathine) Acts via D1/D2-like dopamine receptors inthe nucleus accumbens shell. Front Neurosci 2020; 14:572328.

  111. Hauner H, Hastreiter L, Werdier D, Chen-Stute A, ScholzeJ, Blüher M. Efficacy and safety of cathine (nor-pseudoephedrine)in the treatment of obesity: A randomizeddose-finding study. Obes Facts 2017; 10 (4): 407-19. doi:10.1159/000478098.

  112. Del Valle-Laisequilla CF, Trejo-Jasso C, Huerta-Cruz JC, Barranco-Garduño LM, Rodríguez-Silverio J, Rocha-González HI,Reyes-García JG. Efficacy and safety of a fixed-dose combinationof D-norpseudoephedrine, triiodothyronine, atropine,aloin, and diazepam in obese patients. Int J Clin PharmacolTher 2018; 56 (11): 531-538. doi: 10.5414/CP203292.

  113. Filippatos TD, Derdemezis CS, Gazi IF, Nakou ES, MikhailidisDP, Elisaf MS. Orlistat-associated adverse effects and druginteractions: a critical review. Drug Saf 2008; 31 (1): 53-65.doi: 10.2165/00002018-200831010-00005.

  114. Lei X-G, Ruan J-Q, Lai C, Sun Z, Yang X. Efficacy and safety ofphentermine/topiramate in adults with overweight or obesity:A systematic review and meta-analysis. Obesity (SilverSpring) 2021; 29 (6): 985-94. doi: 10.1002/oby.23152.

  115. Douglas A, Douglas JG, Robertson CE, Munro JF. Plasmaphentermine levels, weight loss and side-effects. Int J Obes1983; 7 (6): 591-5.

  116. Zhong P, Zeng H, Huang M, Fu W, Chen Z. Efficacy and safetyof once-weekly semaglutide in adults with overweight orobesity: a meta-analysis. Endocrine 2022; 75 (3): 718-24.doi: 10.1007/s12020-021-02945-1.

  117. Caixàs A, Albert L, Capel I, Rigla M. Naltrexone sustainedrelease/bupropion sustained-release for the managementof obesity: review of the data to date. Drug Des Devel Ther2014; 8: 1419-27. Doi 10.2147/DDDT.S55587.

  118. Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A, GrantJR, et al. DrugBank 5.0: A major update to the DrugBankdatabase for 2018. Nucleic Acids Res 2018; 46 (D1): D1074-82. https://doi.org/10.1093/nar/gkx1037.

  119. VigiAccess [Internet]. [cited 2023 Jan 2]. Available from:https://www.vigiaccess.org/.

  120. Lin Q, Xue Y, Zou H, Ruan Z, Ung COL, Hu H. Efficacyand safety of liraglutide for obesity and people who areoverweight: a systematic review and meta-analysis of randomizedcontrolled trials. Expert Rev Clin Pharmacol 2022;15 (12): 1461-9. doi: 10.1080/17512433.2022.2130760.

  121. Finer N. Future directions in obesity pharmacotherapy.Eur J Intern Med 2021; 93: 13-20. doi: 10.1016/j.ejim.2021.04.024.

  122. Ryan DH. Next generation antiobesity medications: Setmelanotide,semaglutide, tirzepatide and bimagrumab:What do they mean for clinical practice? J Obes MetabSyndr 2021; 30 (3): 196-208. doi: 10.7570/jomes21033.

  123. Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, ConneryL, Alves B, et al. Tirzepatide once weekly for the treatmentof obesity. N Engl J Med 2022; 387 (3): 205-16. DOI:10.1056/NEJMoa2206038.

  124. Tak YJ, Lee SY. Long-term efficacy and safety of anti-obesitytreatment: Where do we stand? Curr Obes Rep 2021; 10(1): 14-30. doi: 10.1007/s13679-020-00422-w.

  125. Behary P, Tharakan G, Alexiadou K, Johnson N, WewerAlbrechtsen NJ, Kenkre J, et al. Combined GLP-1, oxyntomodulin,and peptide YY improves body weight and glycemiain obesity and prediabetes/type 2 diabetes: A randomized,single-blinded, placebo-controlled study. Diabetes Care2019; 42 (8): 1446-53. doi: 10.2337/dc19-0449.

  126. Tillner J, Posch MG, Wagner F, Teichert L, Hijazi Y, EinigC, et al. A novel dual glucagon-like peptide and glucagonreceptor agonist SAR425899: Results of randomized,placebo-controlled first-in-human and first-in-patient trials.Diabetes Obes Metab 2019; 21 (1): 120-8. doi: 10.1111/dom.13494.

  127. Astrup A, Madsbad S, Breum L, Jensen TJ, Kroustrup JP,Larsen TM. Effect of tesofensine on bodyweight loss,body composition, and quality of life in obese patients:a randomised, double-blind, placebo-controlled trial.Lancet 2008; 372 (9653): 1906-13. doi: 10.1016/S0140-6736(08)61525-1.

  128. Fuchs T, Loureiro M, Both GH, Skraba HH, Costa-CasagrandeTA. The role of the sleeve gastrectomy and the managementof type 2 diabetes. Arq Bras Cir Dig 2017; 30 (4):283-6. doi: 10.1590/0102-6720201700040013.

  129. Pacheco-Sánchez D, Pinto-Fuentes P, Asensio-Díaz E. Actualizaciónen cirugía bariátrica/metabólica. Nutr Clin Med2019; XIII: 113-27. DOI: 10.7400/NCM.2019.13.2.5077.

  130. Guía de Práctica Clínica. Tratamiento quirúrgico del pacienteadulto con obesidad mórbida. CENETEC 2018.

  131. De Lorenzo A, Soldati L, Sarlo F, Calvani M, Di Lorenzo N,Di Renzo L. New obesity classification criteria as a tool forbariatric surgery indication. World J Gastroenterol. 2016;22 (2): 681-703. doi: 10.3748/wjg.v22.i2.681.

  132. Salgado SM, Ryou M. Novel endoscopic bariatric therapies:A glimpse into the future. Tech Gastrointest Endosc 2017;19: 33-40. https://doi.org/10.1016/j.tgie.2016.12.003.

  133. Choi HS, Chun HJ. Recent trends in endoscopic bariatrictherapies. Clin Endosc. 2017; 50 (1): 11-6. doi: 10.5946/ce.2017.007.




2020     |     www.medigraphic.com